

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

PROPOSED RE-ELECTION AND APPOINTMENTS OF DIRECTORS OF THE SECOND SESSION OF THE BOARD

The term of office of the first session of the Board of Sunshine Lake Pharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) will soon expire.

In accordance with relevant provisions of the Company Law of the People's Republic of China and the articles of association of the Company, and upon the recommendation of the Nomination Committee, the Board has proposed: (1) the re-election of Dr. Zhang Yingjun an executive Director of the second session of the Board; (2) the re-election of Dr. Li Wenjia and the redesignation of her from an executive Director of the first session of the Board to an non-executive Director of the second session of the Board; (3) the re-election of Mr. Zhang Yushuai, Mr. Tang Xinfu and Mr. Zhu Yingwei as non-executive Directors of the second session of the Board; (4) the re-election of Dr. Li Xintian, Dr. Ma Dawei, Dr. Lin Aimei and Dr. Ye Tao as independent non-executive Directors of the second session of the Board; (5) the appointment of Mr. Jiang Juncai as an executive Director of the second session of the Board.

In accordance with the requirements of relevant laws, regulations and the Articles of Association, the above-mentioned proposed appointments of the Directors of the second session of the Board are subject to the approval by the Shareholders at the general meeting. The term of office of each of the above-mentioned Director candidates shall be valid for three years commencing from the date of consideration and approval by the general meeting of the Company.

The biographical details of the Director candidates proposed to be re-elected or appointed are set out below:

Candidates for executive Directors

Dr. Zhang Yingjun (張英俊博士), aged 48, is the chairman of the Company and an executive Director and is primarily responsible for long-term strategic planning and overall corporate operation of the Group, and R&D of drugs. Dr. Zhang joined the Group in April 2008 and was elected as a Director of the Company at the general meeting of the Company on January 19, 2021. He was designated as an executive Director of the Company on May 10, 2024. Dr. Zhang is the chairman of the strategic committee of the Board and a member of the Nomination Committee and the Remuneration and Appraisal Committee. Dr. Zhang has also served as an executive director of Dongguan HEC Medicine R&D Co., Ltd.* (東莞市東陽光新藥研發有限公司) since March 2019.

Dr. Zhang has over 18 years of experience in R&D of innovative drugs and business management. Dr. Zhang joined the Group in 2008, he is currently the chairman of the Board and the head of the drug research department of the Company, mainly responsible for R&D and development of drugs, long-term strategy, strategic planning and major decisions of the Group. Dr. Zhang has also served as the executive deputy director and a member of the academic committee of the State Key Laboratory for New Anti-Infective Drugs Development starting from April 2023. Prior to joining the Group, Dr. Zhang conducted post-doctoral research at Okayama University of Science in Japan from November 2007 to March 2008, focusing on the synthesis of complex molecules and the synthesis of organic light-emitting material compounds.

Dr. Zhang is a recipient of the State Council Special Allowance and has received a number of accolades, including the “First Prize of the Guangdong Science and Technology Progress Award” (廣東省科技進步一等獎) awarded by People’s Government of Guangdong Province in August 2024, the “Second Prize of the Beijing Science and Technology Award” (北京市科學技術獎二等獎) issued by the Beijing Municipal Government in October 2023, the “First Prize of the 2023 Innovation Dongguan Science and Technology Progress Award” (2023年創新東莞科技進步獎一等獎) awarded by the Dongguan High-tech Industrial Association, the title of “Top Ten Innovative Figures of Dongguan City” (東莞市十大創新人物) awarded by the High-Tech Industry Association in May 2018, the title of Guangdong Special Support Program — Leading Talent in Scientific and Technological Innovation (廣東特支計劃 — 科技創新領軍人才) awarded by the Guangdong Provincial Science and Technology Department (廣東省科學技術廳) in April 2017, the title of Innovative Talent Promotion Program — Leading Talent in Science and Technology Innovation for Middle-Aged and Young Professionals (創新人才推進計劃中青年科技創新領軍人才) awarded by the Ministry of Science and Technology in March 2014, and the title of “Outstanding Science and Technology Personnel of Dongguan City” (東莞市科技優秀工作者) awarded by from Dongguan Science and Technology Association (東莞市科學技術協會) in February 2015.

Furthermore, Dr. Zhang has held multiple academic positions, including the vice chairman of Nanjing Innovation and Transformation of Biomedical Industry Center (南京生物醫藥產業創新轉化中心副理事長) in 2023, an executive director of Chinese Biomedical Industry Innovation and Transformation Alliance (中國生物醫藥產業鏈創新與轉化聯盟常務理事) in 2023, senior member of the Pharmaceutical Chemistry Committee of Guangdong Province (廣東省藥物化學委員會主任委員) in 2022, Deputy Chairman of the Second Committee of Drug Screening and Evaluation at the Guangdong Pharmacology Society (廣東省藥理學會第二屆藥物篩選與評價專業委員會副主任委員) in 2021, committee member of the Medicinal Chemistry Professional Committee of the Chinese Pharmaceutical Association (中國藥學會藥物化學專業委員會委員) in 2020, youth editor for the journal “Progress in Pharmacy” (《藥學進展》) in 2019, and technical expert in patent examination for the China National Intellectual Property Administration in 2017. Dr. Zhang has also served as the person in charge of the National Major Scientific and Technological Special Project for “Significant New Drugs Development” (“重大新藥創制”科技重大專項) (Project no. 2013ZX09101003)

Dr. Zhang was recognized as a senior engineer in pharmaceuticals (associate senior) (製藥高級工程師(副高級)) by the Human Resources and Social Security Bureau of Shenzhen Municipality in July 2023.

Dr. Zhang obtained a bachelor’s degree in chemistry from Hunan University in June 2001; a master’s degree in organic chemistry from Hunan University in June 2004; and a doctorate degree in organic chemistry from Hunan University in December 2007.

As of the date of this announcement, Dr. Zhang, being the sole general partner, controls Yidu Fangwenwen and Yidu Yingwenfang. By virtue of the SFO, Dr. Zhang is deemed to be interested in the 11,477,892 H Shares held by Yidu Fangwenwen and the 11,477,892 H Shares held by Yidu Yingwenfang, respectively.

Mr. JIANG Juncai (蔣均才), aged 44, joined the Group in May 2015, and served as an executive director and the general manager of the Yichang HEC ChangJiang Pharmaceutical Co., Ltd., (宜昌東陽光長江藥業股份有限公司) from May 2015 to August 2025.

Mr. Jiang served as a director of Yidu HEC Industrial Development Co., Ltd. (宜都市東陽光實業發展有限公司) from March 2012 to May 2015. Prior to that, Mr. Jiang was a director of Yichang Shancheng Cordyceps Sinensis Co., Ltd. (宜昌山城水都冬蟲夏草有限公司) from March 2012 to July 2015, and successively served as a researcher at the biochemistry division, a researcher and deputy head of the traditional Chinese medicine division and the deputy head of the zoological and botanical division of Sunshine Lake Pharma from July 2006 to May 2012.

Mr. Jiang graduated with a master’s degree in science from Shenyang Pharmaceutical University (瀋陽藥科大學) in June 2006.

As of the date of this announcement, Mr. Jiang directly held 17,609 H Shares.

Candidates for non-executive Directors

Mr. Zhang Yushuai (張寓帥先生), aged 38, is a non-executive Director of the Company. Mr. Zhang was elected as a Director at the general meeting of the Company on December 5, 2023 and was designated as a non-executive Director of the Company on May 10, 2024. Mr. Zhang is primarily responsible for providing guidance for the overall development of the Group.

Mr. Zhang has over 14 years of experience in corporate management and operations. Mr. Zhang has been serving as the chairman of the board of directors of Shenzhen HEC Industrial since August 2020, mainly responsible for corporate management and operation. He served as a director of Guangdong HEC Technology (whose shares are listed on the Shanghai Stock Exchange (stock code: 600673)) from January 2017 to April 2021 and has been serving as a director of Yichang HEC Medicine since June 2015. In addition, Mr. Zhang also worked for Dongguan HEC Research from July 2011 to May 2014, serving as the director of the Institute of Biology, the director of the Generic Pharmaceuticals Department and the deputy director of the Research Institute, and was mainly responsible for their management and operations of the business.

Mr. Zhang obtained a bachelor's degree in law through distance learning from Wuhan University in March 2012.

As of the date of this announcement, Shenzhen HEC Industrial is interested in, both directly and indirectly, 169,226,726 Domestic Shares and 86,485,967 H Shares, and is owned as to 42.34% by Ruyuan Yuneng Electric, 27.01% by Shaoguan Xinyuneng Industrial, and 30.66% by Ruyuan Xinjing Technology. Shaoguan Xinyuneng Industrial is owned as to 58% and 42% by Ruyuan Yuneng Electric and Ruyuan Xinjing Technology, respectively. Ruyuan Yuneng Electric is in turn owned as to 99.19% by Mr. Zhang, and 0.50% by Ruyuan Shuaicai Investment, a limited partnership established under the laws of the PRC with Mr. Zhang Yushuai being its general partner and holding 90% interest therein. Ruyuan Xinjing Technology is in turn owned as to 75.00% by Mr. Zhang Yushuai. Therefore, Mr. Zhang Yushuai is deemed to be interested in all Shares which Shenzhen HEC Industrial is interested in for the purpose of the SFO.

Further, as of the date of this announcement, Yidu Shuaixinwei and Yidu Junjiafang held 30,607,250 and 7,651,813 H Shares, respectively. Mr. Zhang is the general partner of each of Yidu Shuaixinwei and Yidu Junjiafang. Therefore, Mr. Zhang is deemed to be interested in all Shares held by Yidu Shuaixinwei and Yidu Junjiafang for the purpose of the SFO.

Mr. Tang Xinfu (唐新發先生), aged 55, is a non-executive Director of the Company. Mr. Tang joined the Group in September 2005. He was elected as a Director at the general meeting of the Company on November 25, 2010 and was designated as a non-executive Director on May 10, 2024. Mr. Tang is a member of the Audit Committee. Mr. Tang has also been the chairman of Dongguan HEC Medical since January 2017 and the chairman and non-executive director of HEC CJ Pharm since May 2015. Mr. Tang is primarily responsible for providing guidance on the overall development of the Group.

Mr. Tang has approximately 23 years of experience in corporate operations management. Mr. Tang has held management positions in a number of companies and is primarily responsible for corporate management and decision-making, including as an executive director and manager of Guangzhou Yangzhiguang Trading Co., Ltd.* (廣州陽之光貿易有限公司) since January 2022; and an executive director of Ruyuan Yao Autonomous County Taidong Pharmaceutical Co., Ltd.* (乳源瑤族自治縣泰東藥業有限公司), an executive director and manager of Yidu Tang Junyi Health Industry Development Co., Ltd.* (宜都唐俊義健康產業發展有限公司) and Yidu Tang Juntao Pharmaceutical Technology Co., Ltd.* (宜都唐俊濤醫藥科技有限公司) since September 2019. Mr. Tang has also been a director and manager of Dongguan HEC Gaoneng Medical Equipment Co., Ltd.* (東莞東陽光高能醫療設備有限公司) since August 2018 and an executive director and general manager of Linzhi HEC Pharmaceutical Research since December 2016. Mr. Tang has also been a director and general manager of Shenzhen HEC Industrial since November 2015; the chairman of Dongguan HEC Industrial Development Co., Ltd.* (東莞市東陽光實業發展有限公司) since June 2015; and an executive director and manager of Yichang HEC Research since December 2014. Mr. Tang has been a director of Yichang HEC Medicine since December 2010; an executive director and manager of Dongguan HEC Research since September 2010; a director of Guangdong Southern China Advanced Pharmaceutical Co., Ltd.* (廣東華南新藥創製有限公司) since September 2008; the director of the Institute of Research of the Company from September 2005 to September 2010; and the director of the office of Shenzhen HEC Industrial from September 2002 to September 2005.

Mr. Tang obtained a master's degree in Literary Studies from the Department of Chinese of Xiamen University in September 2002.

As of the date of this announcement, Mr. Tang is interested in 5,652,977 H Shares through his partnership interest in Yidu Yingwenfang and directly held 34,375 H Shares, respectively.

Mr. Zhu Yingwei (朱英偉先生), aged 55, is a non-executive Director of the Company. Mr. Zhu joined the Group in August 2001. He was appointed as a Director at the general meeting of the Company on December 29, 2003 and was designated as a non-executive Director on May 10, 2024. Mr. Zhu is primarily responsible for providing guidance on the overall development of the Group.

Mr. Zhu has approximately 28 years of experience in business operations and management. Mr. Zhu has held various management positions in a number of companies and is primarily responsible for corporate management and decision-making, including as executive director and manager of Dongyang HEC Industrial Development Co., Ltd.* (東陽市東陽光實業發展有限公司) since January 2021; the director and general manager of Yichang HEC Medicine since December 2010; non-executive director of HEC CJ Pharm from August 2001 to May

2017 and Chairman of the Company from December 2009 to January 2021. Mr. Zhu also has been serving as the general manager of Yidu HEC Industrial since February 2004 and was a director thereof; the deputy general manager of Shenzhen HEC Industrial from September 1997 to January 2021 and a director thereof from November 2020 to date.

Mr. Zhu was the executive director of the Pharmaceutical Profession Association of Hubei Province from April 2012 to April 2015 and has been serving as the vice president of the Yichang Foreign Investment Association since December 2007. Mr. Zhu was recognized as a senior engineer in pharmaceutical engineering by the Professional Title Reformation Office of Hubei in July 2009. In April 2019, he was recognized as a senior economist by the Professional Title Reform Steering Group (湖北省職稱改革工作領導小組). In February 2026, he was recognized as a Senior Engineer of Pharmaceutical Production and Operation by the Professional Title Reform Steering Group.

Mr. Zhu graduated from Jilin University in July 1993 with a bachelor's degree in electronic materials and components.

As of the date of this announcement, Mr. Zhu is interested in 4,612,910 H Shares through his partnership interest in Yidu Shuaixinwei.

Dr. Li Wenjia (李文佳博士), aged 43, is an executive Director and the general manager of the Company and is primarily responsible for management of the Group and R&D of biologics. Dr. Li joined the Group in July 2006 and was elected as a Director and general manager of the Company at the general meeting of the Company on January 19, 2021. She was designated as an executive Director on May 10, 2024. Dr. Li has also served as an executive director of Dongguan HEC Biopharmaceutical since March 2019.

Dr. Li has over 19 years of experience in R&D of biologics and management. Dr. Li joined the Group in July 2006 and has held various positions. She is currently the general manager of the Company and the deputy head of the drug research department of the Company, mainly responsible for R&D of biologics and management. Dr. Li also served as an executive director and manager of Guangdong HEC Biopharmaceutical from February 2017 to April 2020, primarily responsible for participating in the planning and formulation of the Company's long-term development strategies and development plans and overseeing their implementation.

Dr. Li was recognized as a senior engineer in pharmaceuticals (senior) (製藥正高級工程師(正高級)) by the Human Resources and Social Security Department of Guangdong Province in March 2019.

Dr. Li obtained a bachelor's degree in biotechnology from China Pharmaceutical University in July 2003; a master's degree in microbiology and biochemical pharmacy from China Pharmaceutical University in June 2006; and a doctoral degree in microbiology from the University of Chinese Academy of Sciences in January 2024.

As of the date of this announcement, Dr. Li is interested in 850,947 H Shares through her partnership interest in Yidu Yingwenfang.

Candidates for independent non-executive Directors

Dr. Li Xintian (李新天博士), aged 61, is an independent non-executive Director of the Company, and is primarily responsible for providing independent advice and judgment to the Board so as to protect the overall interests of the Company. Dr. Li was appointed as a Director in a general meeting of the Company on September 15, 2023, and was designated as an independent non-executive Director on May 10, 2024. Dr. Li is a member of the Audit Committee and the Remuneration and Appraisal Committee.

Dr. Li has over 31 years of experience in legal research in civil and commercial matters. Dr. Li had been working as a part-time lawyer of Beijing Jintai (Wuhan) Law Office* (北京金台(武漢)律師事務所) since November 2003 and the part-time vice chairman of the Labor Union of Wuhan University from March 2012 to June 2015. Dr. Li has also been teaching the Civil and Commercial Law Teaching and Research Section of Wuhan University Law School since September 1992. He was a professor and doctoral supervisor in the field of civil and commercial law in 2025. He worked in the Discipline Inspection Committee of Wuhan University from July 1989 to September 1992. Dr. Li officially retired in August 2025.

Since May 2018, Dr. Li has served as an independent non-executive director of iDreamSky Technology Holdings Limited (創夢天地科技控股有限公司), the shares of which are listed on the Stock Exchange (stock code: 01119), principally engaged in digital entertainment platform services for mobile game distribution market. Dr. Li has been an independent non-executive director of Changjiang Securities Co., Ltd. (stock code: 000783) since December 2025.

Dr. Li has been accredited as a professor by Wuhan University since October 2005.

Dr. Li obtained a bachelor's degree in law from Wuhan University in July 1989, completed a master's program in economic law from Wuhan University in August 1997, and obtained a doctorate degree in international jurisprudence from Wuhan University in June 2002.

Dr. Ma Dawei (馬大為博士), aged 62, is an independent non-executive Director of the Company, and is primarily responsible for providing independent advice and judgment to the Board so as to protect the overall interests of the Company. Dr. Ma was appointed as a Director in a general meeting of the Company on September 15, 2023, and was designated as an independent non-executive Director on May 10, 2024.

Dr. Ma has over 31 years of experience in biochemical research. Dr. Ma has been serving as an assistant researcher, a researcher and a doctoral tutor at the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, and the director of the State Key Laboratory of Bioorganic Chemistry since July 1989, mainly engaged in scientific research guidance.

Dr. Ma has been and is currently on the editorial boards of a number of international journals, including:

- Natural Product Reports, serving as advisory board member.
- Advanced Synthesis & Catalysis, serving as academic advisory board member.
- Tetrahedron/Tetrahedron Letters, serving as advisory board member.

Dr. Ma has been serving as an independent director of Shanghai Medicilon Inc.* (上海美迪西生物醫藥股份有限公司), the shares of which are listed on the Shanghai Stock Exchange (stock code: 688202) from November 2021 to May 2025.

Dr. Ma obtained a number of honors, including the Material Science Award of the 3rd Future Science Award (第三屆未來科學大獎物質科學獎) (on September 8, 2018), the National Outstanding Scientist (全國優秀科技工作者) (on December 7, 2010), the 2007 WuXi Biosciences Research Award (first prize) (藥明康德生命化學研究獎一等獎), etc.

Dr. Ma received his master of science degree from the Shanghai Institute of Organic Chemistry (上海有機化學研究所) in December 1986, and his doctoral degree in chemistry from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in May 1989.

Dr. Lin Aimei (林愛梅博士), aged 59, is an independent non-executive Director and is primarily responsible for providing independent advice and judgment to the Board so as to protect the overall interests of the Company. Dr. Lin was appointed as a Director in the general meeting of the Company on September 15, 2023, and was designated as an independent non-executive Director on May 10, 2024. Dr. Lin is the chairman of the Audit Committee and the Remuneration and Appraisal Committee and a member of the Nomination Committee.

Dr. Lin has over 36 years of experience in accounting and corporate management. Dr. Lin has been serving as an independent director of Jiangsu Xinhua Semiconductor Technology Co., Ltd.* (江蘇鑫華半導體科技股份有限公司) since December 2022 and Xuzhou Hengxin Financial Leasing Co., Ltd.* (徐州恒鑫金融租賃股份有限公司) since January 2023. Since August 1989, Dr. Lin has worked in the accounting department of the School of Economics and Management, China University of Mining and Technology, and currently serves as a professor and doctoral supervisor.

From December 2014 to January 2021, Dr. Lin served as an independent director of XCMG Construction Machinery Co., Ltd.* (徐工集團工程機械股份有限公司), the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000425), during which period Dr. Lin served as a member of the audit committee from January 2015 to January 2021. From November 2017 to September 2023, Dr. Lin served as an independent director of Jiangxi Chen Guang New Materials Co., Ltd.* (江西晨光新材料股份有限公司), (“**Chen Guang New Materials**”) the shares of which are listed on the Shanghai Stock Exchange (stock code: 605399). During the period, Dr. Lin served as the chairman of the audit committee of Chen Guang New Materials from October 2020 to September 2023. Dr. Lin was also an independent director of Jiangsu Wuyang Parking Industry Group Co., Ltd.* (江蘇五洋停車產業集團股份有限公司) (“**Wuyang Parking**”) from November 2017 to November 2023, the shares of which are listed on the Shenzhen Stock Exchange (stock code: 300420). During the period, Dr. Lin served as a member of the audit committee of Wuyang Parking from November 2020 to November 2023. Dr. Lin has also served as an independent director and the chairman of the audit committee of Guosheng Shian Technology Co., Ltd.* (國晟世安科技股份有限公司) since September 2023, the shares of which are listed on the Shanghai Stock Exchange (stock code: 603778), and is primarily engaged in information technology consulting services and urban greening management.

Dr. Lin has received a number of honors, including: first prize of China Coal Industry Science and Technology Award (中國煤炭工業科學技術獎) issued by China National Coal Association in November 2010; second prize of China Coal Industry Science and Technology Award (中國煤炭工業科學技術獎) issued by China National Coal Association in November 2011, respectively; first prize of Jiangsu Province Coal Science and Technology Progress Award issued by Jiangsu Coal Mine Safety Supervision Bureau (江蘇煤礦安全監督局) in October 2009 and second prize for Jiangsu Provincial Teaching Achievement Award (Higher Education Category) (江蘇省教學成果獎(高等教育類)) awarded by Jiangsu Provincial Department of Education in September 2017, and other honorary titles.

Dr. Lin obtained a bachelor's degree in financial accounting from China University of Mining and Technology in June 1989, a master's degree in accounting from China University of Mining and Technology in June 1998, and a doctorate degree in management science and engineering from China University of Mining and Technology in December 2009.

Dr. Ye Tao (葉濤博士), aged 63, is an independent non-executive Director and is primarily responsible for providing independent advice and judgment to the Board so as to protect the overall interests of the Company. Dr. Ye was appointed as an independent non-executive Director at a general meeting of the Company on December 11, 2024 (effective upon Listing).

Dr. Ye has over 31 years of experience in chemical biology research. Dr. Ye has served as a professor and doctoral supervisor in the School of Chemical Biology and Biotechnology, Shenzhen Graduate School of Peking University since October 2015 and concurrently served as the executive deputy dean thereof from March 2018 to October 2023, and is mainly responsible for academic research and teaching and daily management. Prior to that, Dr. Ye worked at the Hong Kong Polytechnic University from December 2001 to August 2015 as a senior researcher and an associate professor, mainly responsible for supervising PhD students in research and teaching undergraduate courses. Dr. Ye served as a research assistant professor at the University of Hong Kong from December 1998 to December 2001, mainly responsible for guiding PhD students in research and teaching undergraduate courses. Dr. Ye engaged in postdoctoral research at Queen's University of Belfast from July 1993 to July 1994 and at the University of Nottingham from July 1994 to September 1998.

Dr. Ye was elected as a Fellow of the Royal Society of Chemistry in May 2015.

Dr. Ye obtained a bachelor's degree in pharmaceutical chemical industry from East China Institute of Chemical Technology (currently known as East China University of Science and Technology) in December 1983, and a master's degree in fine chemicals from East China University of Science and Technology in July 1986. He received his doctorate degree from Queen's University of Belfast in the United Kingdom in July 1993.

Upon appointment, the Company will enter into a service contract with each Director.

Each of the above independent non-executive Director candidates has respectively confirmed that, as of the date of this announcement, (i) he/she meets the independence requirement in relation to each of the factors set out in Rules 3.13(1) to (8) of the Listing Rules; (ii) he/she has no past or present financial or other interests in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his/her independence at the time of his/her appointment. The Nomination Committee and the Board have assessed and consider that each of the proposed independent non-executive Directors meets the independence requirements set out in Rule 3.13 of the Listing Rules.

Saved as disclosed herein, as of the date of this announcement, each of the Director candidates of the second session of the Board has confirmed that: (1) he/she does not hold any other position with the Company or any of its subsidiaries and has not been a director in any other listed companies during the past three years; (2) he/she has no relationship with any other Directors, supervisors, senior management, controlling or substantial shareholders of the Company; and (3) he/she does not have any interest in the Shares of the Company within the meaning of Part XV of the SFO.

Each of the Director candidates of the session of the Board has also confirmed that there is no other information in relation to his/her re-election or appointment that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules, and there is no other matter in relation to his/her re-election or appointment that needs to be brought to the attention of the Hong Kong Stock Exchange and Shareholders.

If appointed, (1) the executive Director of the second session of the Board will receive remuneration based on their respective senior management positions within the Company, but will not receive remuneration in respect of his/her role as an executive Director; (2) the non-executive Director of the second session of the Board will not receive remuneration in respect of his/her role as a non-executive Director; and (3) the independent non-executive Director of the second session of the Board shall be entitled to RMB150,000 (tax inclusive) per annum. The remuneration of the proposed independent non-executive Directors was determined in accordance with the Company's remuneration policy and with reference to the level of remuneration paid by comparable companies, time commitment of the Directors, duties and responsibilities in the Group, their qualifications and experience. The Company will disclose the total remuneration received by the Directors in the annual report accordingly.

Mr. Zeng Xuebo, Ms. Dong Xiaowei, Ms. Wang Lei and Dr. Yin Hang Hubert will not seek re-election to the second session of the Board due to change of board session and will retire from their respective position as non-executive Director and independent non-executive Directors, respectively. Each of Mr. Zeng Xuebo, Ms. Dong Xiaowei, Ms. Wang Lei and Dr. Yin Hang Hubert has confirmed that they have no disagreement with the Board and there are no other matters relating to their respective retirements that need to be brought to the attention of the Hong Kong Stock Exchange and Shareholders.

The Company will also hold an employee representative meeting to elect the employee Director of the second session of the Board in accordance with the Articles of Association in due course.

Circular

A circular containing, among other things, further details of the proposed re-election and appointment of Directors of the session session of the Board, together with the notice of the general meeting, will be published on the websites of the Stock Exchange and the Company, and (if requested) despatched to the Shareholders as and when appropriate.

Definitions

In this announcement, unless the context otherwise requires, the following terms shall have the following meanings:

“Articles of Association”	the articles of association of the Company, as amended from time to time
“Audit Committee”	the audit committee of the Board
“Board”	the board of Directors
“China” or “PRC”	the People’s Republic of China, which for the purpose of the announcement and for geographical reference only, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Company”, “the Company”	Sunshine Lake Pharma Co., Ltd. (廣東東陽光藥業股份有限公司), the H Shares of which are listed on the Hong Kong Stock Exchange (stock code: 6887)
“Company Law”	the Company Law of the People’s Republic of China (《中華人民共和國公司法》)
“Director(s)”	the director(s) of the Company or any one of them
“Group”	the Company and its wholly-owned subsidiaries
“H Share(s)”	ordinary share(s) in the share capital of the Company with nominal value of RMB1.00 each, which are listed on the Hong Kong Stock Exchange
“HK\$”	Hong Kong dollars and cents, both are the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Listing Rules”	the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (as amended from time to time)
“Nomination Committee”	the nomination committee of the Board

“Remuneration and Evaluation Committee”	The remuneration and evaluation committee of the Board
“RMB”	Renminbi, the lawful currency of the PRC
“Ruyuan Shuaicai Investment”	Ruyuan Yao Autonomous County Shuaicai Investment Service Partnership (L.P.)* (乳源瑤族自治縣帥才投資服務合夥企業(有限合夥))
“Ruyuan Xinjing Technology”	Ruyuan Yao Autonomous County Xinjing Technology Development Co., Ltd.* (乳源瑤族自治縣新京科技發展有限公司)
“Ruyuan Yuneng Electric”	Ruyuan Yao Autonomous County Yuneng Electric Industrial Co., Ltd.* (乳源瑤族自治縣寓能電子實業有限公司)
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Shaoguan Xinyuneng Industrial”	Shaoguan Xinyuneng Industrial Investment Co., Ltd.* (韶關新寓能實業投資有限公司)
“Share(s)”	the share(s) with a nominal value of RMB1.00 each in the capital of the Company
“Shareholder(s)”	holder(s) of Shares
“Shenzhen HEC Industrial”	Shenzhen HEC Industrial Development Co., Ltd.* (深圳市東陽光實業發展有限公司)
“Yidu Fangwenwen”	Yidu Fangwenwen Equity Investment Limited (L.P.)* (宜都芳文文股權投資合夥企業 (有限合夥))
“Yidu Junjiafang”	Yidu Junjiafang Equity Investment Limited (L.P.)* (宜都俊佳芳股權投資合夥企業 (有限合夥))
“Yidu Shuaixinwei”	Yidu Shuaixinwei Equity Investment Limited (L.P.)* (宜都帥新偉股權投資合夥企業 (有限合夥))
“Yidu Yingwenfang”	Yidu Yingwenfang Equity Investment Limited (L.P.) (宜都英文芳股權投資合夥企業 (有限合夥))
“%”	percentage

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Zhang Yingjun
Chairman

Hong Kong, 28 May 2026

As at the date of this announcement, the executive Directors are Dr. Zhang Yingjun, Dr. Li Wenjia; the non-executive Directors are Mr. Zhang Yushuai, Mr. Tang Xinfu, Mr. Zhu Yingwei, Mr. Zeng Xuebo, Ms. Dong Xiaowei, Ms. Wang Lei; the independent non-executive Directors are Dr. Li Xintian, Dr. Ma Dawei, Dr. Yin Hang Hubert, Dr. Lin Aimei and Dr. Ye Tao.

** For identification purpose only*